Effexor Script Growth Will Double Antidepressant Market Rate, Wyeth Predicts
This article was originally published in The Pink Sheet Daily
Executive Summary
Effexor XR scripts grew 4% in the third quarter, compared to 2% growth for the category, Wyeth says. Sales of the antidepressant franchise jumped 46% in the U.S. in the third quarter. The company predicts “black box” class warning will not significantly impact Effexor, which is not advertised on TV.
You may also be interested in...
Wyeth Sales Growth Not Dependent On Effexor XR, CEO Essner Says
The company plans to file six NDAs over the next 24 months, including the Effexor follow-on drug DVS-233. Wyeth believes the antidepressant market will eventually "start to swing back" since the products are safe and effective "within the confines of their labeling."
Wyeth Sales Growth Not Dependent On Effexor XR, CEO Essner Says
The company plans to file six NDAs over the next 24 months, including the Effexor follow-on drug DVS-233. Wyeth believes the antidepressant market will eventually "start to swing back" since the products are safe and effective "within the confines of their labeling."
GSK Paxil DTC Pullback Decreases Downside From Black Box Requirement
GlaxoSmithKline does not foresee a significant impact from the antidepressant "black box" class warning requirement since it has already pulled back Paxil direct-to-consumer ads